CytoDyn (OTCMKTS:CYDY) Stock Crosses Above 200-Day Moving Average – Should You Sell?

CytoDyn Inc. (OTCMKTS:CYDY)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.28 and traded as high as $0.28. CytoDyn shares last traded at $0.2681, with a volume of 3,466,348 shares changing hands.

CytoDyn Stock Performance

The business has a 50 day moving average of $0.27 and a two-hundred day moving average of $0.28. The stock has a market capitalization of $342.78 million, a PE ratio of -8.94 and a beta of 1.13.

CytoDyn (OTCMKTS:CYDY) last posted its earnings results on Friday, January 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.